To determine whether specific preventive measures reduce the rate of peritoneal catheter-related infections and peritoneal catheter loss due to Staphylococcus aureus.
Design
Structured literature synthesis.
Methods
Relevant studies were identified by medline search, from personal files, and from the reference lists of retrieved articles. We analyzed English-language studies on treatment targeted at S. aureus, with at least 10 subjects and at least 3 months of follow-up, and data on staphylococcal peritoneal dialysis catheter infections. We excluded noncontrolled studies. Two investigators abstracted data using a structured form.
Results
We evaluated six studies with concurrent controls and eight studies with historical controls. In one randomized, placebo-controlled, blinded study, periodic nasal mupirocin ointment reduced the rate of staphylococcal exit-site infection from 0.42 to 0.12 episodes/patient-year (p = 0.006), but had no effect on the rates of staphylococcal tunnel infection, peritonitis, or catheter loss. In one randomized study without placebo control, periodic oral rifampin reduced the rate of staphylococcal exit-site infection from 0.65 to 0.22 epi/pt-yr (p = 0.011), but had no effect on the rate of staphylococcal peritonitis. In another nonblinded, randomized, controlled study, the use of either rifampin or mupirocin was associated with low rates of staphylococcal catheter infections and catheter loss. In one study with historical controls, the rate of staphylococcal exit-site infection and peritonitis was lower after oral rifampin prophylaxis. In seven other studies comparing nasal or exit-site mupirocin to historical controls, the rate of staphylococcal exit-site infection decreased from 0.17 to 0.05 epi/pt-yr, the rate of staphylococcal peritonitis decreased from 0.18 to 0.06 epi/pt-yr, and the rate of catheter loss decreased from 0.09 to 0.05 epi/pt-yr during the mupirocin period.
Conclusion
The literature provides strong evidence that staphylococcal carriage prophylaxis using either oral rifampin or mupirocin ointment in the nares or exit site reduces significantly the rate of exit-site infection due to Staphylococcus aureus. Weaker evidence based on studies with historical controls suggests that rifampin or mupirocin prophylaxis also reduces the rate of staphylococcal peritonitis and peritoneal catheter loss. Studies with a stronger level of evidence are needed to verify this last point.
ZimmermanS.W., O'BrienM., WiedenhoeftF.A., JohnsonC.A.Staphylococcus aureus peritoneal catheter related infections: a cause of catheter loss and peritonitis.Perit Dial Int1988; 8: 191–4.
2.
LuzarM.A.Exit site infection in continuous ambulatory peritoneal dialysis: a review.Perit Dial Int1991; 11: 333–40.
3.
PirainoB.Management of catheter related infections.Am J Kidney Dis1996; 27: 714–18.
SewellC.M., ClarridgeJ., LackeC., WeinmanC.J., YoungE.G.Staphylococcal nasal carriage and subsequent infection in peritoneal dialysis patients.JAMA1982; 248: 1493–5.
6.
DaviesS.J., OggC.S., CameronJ.S., PostonS., NobleW.C.Staphylococcus aureus nasal carriage and subsequent infection in peritoneal dialysis patients.Perit Dial Int1989; 9: 61–4.
7.
SessoR., DraibeS., CasteloA., SatoI., LemeI., BarbosaD.Staphylococcus aureus skin carriage and development of peritonitis in patients on continuous ambulatory peritoneal dialysis.Clin Nephrol1989; 31: 264–8.
8.
LuzarM.A., ColesG.A., FallerB., SlingeneyerA., GeorgeD.D., BriatC.Staphylococcus aureus nasal carriage and infection in patients on continuous ambulatory peritoneal dialysis.N Engl J Med1990; 322: 505–9.
9.
PirainoB., PerlmutterJ.A., HolleyJ.L., BernardiniJ.Staphylococcus aureus peritonitis is associated with Staphylococcus aureus nasal carriage in peritoneal dialysis patients.Perit Dial Int1993; 13(Suppl 2): S332–4.
10.
LyeW.C., LeongS.O., Van der StratenJ., LeeE.S.C.Staphylococcus aureus CAPD-related infections are associated with nasal carriage.Adv Perit Dial1994; 10: 163–5.
11.
WantenC.J.A., van OostO., SchneebergerP.M., KoolenM.I.Nasal carriage and peritonitis by Staphylococcus aureus in patients on continuous ambulatory peritoneal dialysis: a prospective study.Perit Dial Int1996; 16: 352–6.
12.
ZimakoffJ., Bangsgaard–PedersenF., BergenL., Baago–NielsenJ., DaldorphB., EspersenF.Staphylococcus aureus carriage and infections among patients in four haemo- and peritoneal-dialysis centers in Denmark.J Hosp Infect1996; 33: 289–300.
13.
KinwatanakalP., WaradyB.A.Staphylococcus aureus nasal carriage in children receiving long-term peritoneal dialysis.Adv Perit Dial1997; 13: 281–4.
14.
ZimmermanS., AhrensE., JohnsonC., CraigW., LeggettJ., O'BrienM.Randomized controlled trial of prophylactic rifampin for peritoneal dialysis-related infections.Am J Kidney Dis1991; 18: 225–31.
15.
VychytilA., LorenzM., SchneiderB., HorlW.H., Haag–WeberM.New strategies to prevent Staphylococcus aureus infections in peritoneal dialysis patients.J Am Soc Nephrol1998; 9: 669–76.
16.
TwardowskiZ.J., ProwantB.F.Staphylococcus aureus nasal carriage is not associated with increased incidence of exit-site infection with the same organism.Perit Dial Int1993; 13(Suppl 2): S306–9.
17.
Lubrich–BirknerI., SchollmeyerP., BohlerJ.Carrierstatus for nasal staphylococci does not predict infections in CAPD patients.Adv Perit Dial1994; 10: 154–7.
18.
PassadakisP.S., OreopoulosD.G.Searching for evidence-based medical practice.Perit Dial Int1997; 17: 333–7.
19.
PerlT.M., GolubJ.E.New approaches to reduce Staphylococcus aureus nosocomial infection rates: treating S. aureus nasal carriage.Ann Pharmacother1998; 32: S7–16.
20.
CattranD.C.Evidence-based recommendations for the management of glomerulonephritis. Introduction.Kidney Int Suppl1999; 70: S1–2.
21.
LindbladA.S., NovakS.W., NolphK.D.Prognostic factors associated with the first episode of peritonitis. In: Continuous ambulatory peritoneal dialysis in the USA. Final report of the National CAPD Registry 1981–1988. Dordrecht: Kluwer Academic, 1989: 243–52.
22.
ChurchillD.N., TaylorD.W., VasS.I., OreopoulosD.G., BettcherK.D., FentonS.S.A., for the Canadian CAPD Clinical Trials Group. Peritonitis in continuous ambulatory peritoneal dialysis (CAPD): a multi-centre randomized clinical trial comparing the Y connector disinfectant system to standard systems.Perit Dial Int1989; 9: 159–63.
23.
YoungG.A., YoungJ.B., YoungS.M., HobsonS.M., HildrethB., BrownjohnA.M.Nutrition and delayed hyper-sensitivity during continuous ambulatory peritoneal dialysis in relation to peritonitis.Nephron1986; 43: 577–86.
24.
PirainoB., BernardiniJ., CentaP.K., JohnstonJ.R., SorkinM.I.The effect of body weight on CAPD related infections and catheter loss.Perit Dial Int1991; 11: 64–8.
25.
Poole–WarrenL.A., HalletM.D., HoneP.W.Q., BurdenS.H., FarrellP.C.Vaccination for prevention of CAPD associated staphylococcal infection: results of a prospective multicentre clinical trial.Clin Nephrol1991; 35: 198–206.
26.
The Mupirocin Study Group.Nasal mupirocin prevents Staphylococcus aureus exit-site infection during peritoneal dialysis.J Am Soc Nephrol1996; 7: 2403–8.
27.
SessoR., ParisioK., DalboniA., RabeloT., BarbosaD., GendorogloM.Effect of sodium fusidate and ofloxacin on Staphylococcus aureus colonization and infection in patients on continuous ambulatory peritoneal dialysis.Clin Nephrol1994; 41: 370–6.
28.
BernardiniJ., PirainoB., HolleyJ., JohnstonJ., LutesR.A randomized trial of Staphylococcus aureus prophylaxis in peritoneal dialysis patients: mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin.Am J Kidney Dis1996; 27: 695–700.
29.
SwartzR., MessanaJ., StarmannB., WeberM., ReynoldsJ.Preventing Staphylococcus aureus infection during chronic peritoneal dialysis.J Am Soc Nephrol1991; 2: 1085–91.
30.
ThodisE., BhaskaranS., PassadakisP., BargmanJ.M., VasS.I., OreopoulosD.G.Decrease in Staphylococcus aureus exit-site infections and peritonitis in CAPD patients by local application of mupirocin ointment at the catheter exit site.Perit Dial Int1998; 18: 261–70.
31.
Perez-FontanM., Carcia-FalconT., RosalesM., Rodriguez-CarmonaA., AdevaM., Rodriguez-LozanoI.Treatment of Staphylococcus aureus nasal carriers in continuous ambulatory peritoneal dialysis with mupirocin: long-term results.Am J Kidney Dis1993; 22: 708–12.
32.
MylotteJ.M., KahlerL., JacksonE.“Pulse” nasal mupirocin maintenance regimen in patients undergoing continuous ambulatory peritoneal dialysis.Infect Control Hosp Epidemiol1999; 20: 741–5.
33.
ThodisE., PassadakisP., PanagoutsosS., BacharakiD., EuthimiadouA., VargemezisV.The effectiveness of mupirocin preventing Staphylococcus aureus in catheter-related infections in peritoneal dialysis.Adv Perit Dial2000; 16: 257–61.
34.
CrabtreeJ.H., HadnotL.L., BurchetteR.J., SiddiqiR.A.Outcome and clinical implications of a surveillance program for Staphylococcus aureus nasal carriage in peritoneal dialysis patients.Adv Perit Dial2000; 16: 271–5.
35.
CaseyM., TaylorJ., ClinardP., GrahamA., MauckV., SpainhourL.Application of mupirocin cream at the catheter exit site reduces exit-site infection and peritonitis in peritoneal dialysis patients.Perit Dial Int2000; 20: 566–8.
36.
Perez-FontanM., RosalesM., Rodriguez-CarmonaA., MoncalianJ., Fernandez-RiveraC., CaoM.Treatment of Staphylococcus aureus nasal carriers in CAPD with mupirocin.Adv Perit Dial1992; 8: 242–5.
37.
LowD.E., OreopoulosD.G.Prophylactic cephalexin is ineffective in chronic ambulatory peritoneal dialysis.Lancet1980; ii: 753–4.
38.
ChurchillD.N., TaylorD.W., VasS.I., SingerJ., BeecroftM.C., WuG.Peritonitis in continuous ambulatory peritoneal dialysis (CAPD) patients: a randomized prospective clinical trial of cotrimazole prophylaxis.Perit Dial Int1988; 8: 125–8.
39.
PommerW., BraunerM., WestphaleH.J., BrunkhorstR., KramerR., BundshuD.Effect of a silver device in preventing catheter-related infections in peritoneal dialysis patients: silver ring prophylaxis of the catheter exit site.Am J Kidney Dis1998; 32: 752–60.
40.
TrooskinS.Z., HarveyR.A., LennardT.W.J., GrecoR.S.Failure of demonstrated clinical efficacy of antibiotic-bonded continuous ambulatory peritoneal dialysis (CAPD) catheters.Perit Dial Int1990; 10: 57–9.
HanslickT.M., NewmanL., TessmanM., MorrisseyA.B., FriedlanderM.A.Lack of correlation between nasal cultures positive for Staphylococcus aureus and the development of S. aureus exit-site infection. Results unaffected by routine mupirocin treatment of nasal S. aureus carriage.Adv Perit Dial1994; 10: 158–62.
43.
VasS.I., ConlyJ., BargmanJ.M., OreopoulosD.G.Resistance to mupirocin: no indication of it to date while using mupirocin ointment for prevention of Staphylococcus aureus exit-site infections in peritoneal dialysis patients.Perit Dial Int1999; 19: 313–14.
RaoS.P., OreopoulosD.G.Unusual complications of a polyurethane PD catheter.Perit Dial Int1997; 17: 410–11.
46.
BloweyD., WaradyB., McFarlandK.The treatment of Staphylococcus aureus nasal carriage in pediatric dialysis patients.Adv Perit Dial1994; 10: 297–9.
47.
HavenoldC.D., FisherM.C., WaltzR., BartoshS., BaluarteH.J.Effect of rifampin on Staphylococcus aureus colonization in children on chronic peritoneal dialysis.Pediatr Nephrol1995; 9: 609–11.
48.
DaveyP., CraigA.N., HauC., MalekM.Cost-effectiveness of prophylactic nasal mupirocin in patients undergoing peritoneal dialysis based on a randomized placebo-controlled trial.J Antimicrob Chemother1999; 43: 105–12.
